A PTCE encore virtual symposium affiliated with the 2024 HOPA Annual Conference.
Program Description
While chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) are distinct B-cell malignancies, Bruton tyrosine kinase (BTK) inhibitors have emerged as effective therapeutic options in both disease states. Guideline recommendations for the use of BTK inhibitors in CLL and MCL vary and require that oncology pharmacists are familiar with supporting data for each recommendation when selecting therapies for individual patients. Despite improved response and survival rates, BTK inhibitors are associated with treatment resistance and poor tolerability, resulting in high discontinuation rates. This program will explore treatment expectations with covalent BTK inhibitor therapy and examine how the development of novel noncovalent BTK inhibitors may overcome existing treatment challenges. The discussion will prepare pharmacists to appropriately recommend preferred regimens in CLL and MCL while minimizing serious and frequently encountered adverse effects, including cardiovascular toxicities, optimizing adherence, and improving access to BTK inhibitor therapies.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: May 21, 2024
Expiration date: July 21, 2024
Time to complete activity: 1.0 hour
Learner level: Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Analyze the current guidelines and recommendations for incorporating Bruton tyrosine kinase (BTK) inhibitors into chronic lymphocytic leukemia (CLL) and relapsed/refractory mantle cell lymphoma (R/R MCL) treatment strategies
- Investigate emerging data and ongoing research that may impact the evolving role of BTK inhibitors in CLL and R/R MCL treatment
- Construct a decision-making framework for selecting the most appropriate BTK inhibitor for individual patients based on unique clinical characteristics
- Identify strategies for the proactive management and mitigation of adverse effects of BTK inhibitors, including appropriate dose adjustments, symptom management, and patient counseling
Karen M. Fancher, PharmD, BCOP
Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Clinical Pharmacy Specialist, Oncology
University of Pittsburgh Medical Center Passavant
Pittsburgh, Pennsylvania
Melani A. Rudisill, PharmD, BCOP
Clinical Pharmacy Specialist, Hematology/Transplant and Cellular Therapy
Novant Health Forsyth Medical Center
Winston Salem, North Carolina
Alison Duffy, PharmD, BCOP
Associate Professor
University of Maryland School of Pharmacy
Oncology Clinical Pharmacy Specialist
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-24-111-L01-P. The activity is available for CE credit through July 21, 2024.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
Karen M. Fancher, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:
Consultant: AstraZeneca Pharmaceuticals, LP
Alison Duffy, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Consultant (advisory board): BeiGene
Speakers Bureau: Amgen
Melani A. Rudisill, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy L. Morris, PharmD; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
Daphne Davis, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:
Former employee: GSK
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms